Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment. Local targets link to admitted publications; unresolved targets remain external evidence.
Head and neck squamous cell carcinoma
10.1038/s41572-020-00224-3 · 2020 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
TP53 Mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response
10.1002/jcb.25592 · 2016 · External reference
TP53 mutations in head and neck cancer
10.1002/mc.23385 · 2022 · External reference
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection
10.1016/j.ebiom.2020.102905 · 2020 · External reference
Clinical update on head and neck cancer: molecular biology and ongoing challenges
10.1038/s41419-019-1769-9 · 2019 · External reference
Comprehensive genomic characterization of head and neck squamous cell carcinomas
10.1038/nature14129 · 2015 · External reference
Cancer. p53, guardian of the genome
10.1038/358015a0 · 1992 · External reference
Surfing the p53 network
10.1038/35042675 · 2000 · External reference
TP53 mutation-mediated immune evasion in cancer: mechanisms and therapeutic implications
10.3390/cancers16173069 · 2024 · External reference
TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
10.1007/s11033-023-09097-7 · 2024 · External reference
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
10.1038/s41467-018-03224-w · 2018 · External reference
53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1
10.1038/ncomms3359 · 2013 · External reference
PDL1 Regulation by p53 via miR-34
10.1093/jnci/djv303 · 2016 · External reference
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers
10.1158/2159-8290.cd-13-0103 · 2013 · External reference
Genomic and transcriptomic characterization links cell lines with aggressive head and neck cancers
10.1016/j.celrep.2018.10.007 · 2018 · External reference
Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition
10.1016/j.molonc.2016.04.001 · 2016 · External reference
The coordinate regulation of the p53 and mTOR pathways in cells
10.1073/pnas.0502857102 · 2005 · External reference
The cross talk between p53 and mTOR pathways in response to physiological and genotoxic stresses
10.3389/fcell.2021.775507 · 2021 · External reference
Targeting mTOR in head and neck cancer-response
10.1158/1078-0432.ccr-19-2002 · 2019 · External reference
Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma
10.1002/mc.23357 · 2022 · External reference
Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)
10.18632/oncotarget.28355 · 2023 · External reference
mTOR inhibition augments antitumor T cell response by modulating the expression of immune regulatory molecules
2025 · External reference
Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers
10.1158/2326-6066.cir-15-0252 · 2016 · External reference
mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy
10.3390/ijms20030755 · 2019 · External reference
mTOR inhibition reprograms cellular proteostasis by regulating eIF3D-mediated selective mRNA translation and promotes cell phenotype switching
10.1016/j.celrep.2023.112868 · 2023 · External reference
mTOR: taking cues from the immune microenvironment
10.1111/j.1365-2567.2009.03125.x · 2009 · External reference
mTOR-mediated regulation of immune responses in cancer and tumor microenvironment
10.3389/fimmu.2021.774103 · 2022 · External reference
Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma
10.1038/s42003-022-03675-4 · 2022 · External reference
mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer
10.18632/oncotarget.5063 · 2015 · External reference
Olive leaves extract alleviates inflammation and modifies the intrinsic apoptotic signal in the leukemic bone marrow
10.3389/fimmu.2022.1054186 · 2023 · External reference
Automated fluorometric assay for T cell cytotoxicity
10.1016/0022-1759(88)90042-7 · 1988 · External reference
PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
10.1038/cmi.2014.104 · 2015 · External reference
PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism
10.1002/1878-0261.13103 · 2022 · External reference
Immunotherapeutic potential of ethanolic olive leaves extract (EOLE) and IL-28B combination therapy in ENU induced animal model of leukemia
10.1016/j.cyto.2022.155913 · 2022 · External reference
CXCL9 and CXCL10 bring the heat to tumors
10.1126/sciimmunol.abq6509 · 2022 · External reference
IRF1 transcriptionally up-regulates CXCL10 which increases CD8+ T cells infiltration in colorectal cancer
10.1016/j.intimp.2024.113678 · 2025 · External reference
The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics
10.3390/ijms22052719 · 2021 · External reference
TNF-α increases IP-10 expression in MCF-7 breast cancer cells via activation of the JNK/c-Jun pathways
10.3390/biom11091355 · 2021 · External reference
Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif
10.1074/jbc.m611782200 · 2007 · External reference
mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
10.1038/onc.2014.164 · 2015 · External reference
The mTOR pathway in the control of protein synthesis
2006 · External reference
mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy
10.1073/pnas.1521919112 · 2015 · External reference
Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment
2025 · External reference
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
10.1038/s41388-018-0303-3 · 2018 · External reference
Regulation of PD-L1 expression in the tumor microenvironment
10.1186/s13045-020-01027-5 · 2021 · External reference
PD-1-mediated inhibition of T cell activation: mechanisms and strategies for cancer combination immunotherapy
10.1016/j.cellin.2024.100146 · 2024 · External reference
The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy
10.1186/2047-1440-2-s1-s2 · 2013 · External reference
Combining mTOR inhibitors and T cell-based immunotherapies in cancer treatment
10.3390/cancers13061359 · 2021 · External reference
mTOR signaling at the crossroads of environmental signals and T-cell fate decisions
10.1111/imr.12845 · 2020 · External reference
mTOR regulates memory CD8 T-cell differentiation
10.1038/nature08155 · 2009 · External reference
Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the treg-dendritic cell axis
10.1136/jitc-2020-001955 · 2021 · External reference
Key chemokines direct migration of immune cells in solid tumors
10.1038/s41417-021-00303-x · 2022 · External reference
The multifunctional role of mTOR in innate immunity: implications for transplant immunity
10.1111/j.1600-6143.2009.02832.x · 2009 · External reference
Tumor-infiltrating dendritic cells in cancer pathogenesis
10.4049/jimmunol.1403134 · 2015 · External reference
Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials
10.1016/j.biopha.2024.116930 · 2024 · External reference
Immunosuppressive effects of vascular endothelial growth factor
10.3892/ol.2022.13489 · 2022 · External reference
p53 inhibits hypoxia-inducible factor-stimulated transcription
10.1074/jbc.273.20.11995 · 1998 · External reference
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
10.1111/imm.12036 · 2013 · External reference
The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies
10.1186/s12935-025-03980-y · 2025 · External reference
mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function
10.4049/jimmunol.1401558 · 2014 · External reference
Pd1 and Pdl1 in hpv + and hpv -/Tp53 mutated head and neck squamous cell carcinomas
10.1093/annonc/mdu340.34 · 2014 · External reference
TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas
10.21037/atm-20-1846 · 2020 · External reference
Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma
10.1158/1078-0432.ccr-16-2554 · 2017 · External reference
Searching for the real function of mTOR signaling in the regulation of PD-L1 expression
10.1016/j.tranon.2020.100847 · 2020 · External reference
Enhanced bypass of PD-L1 translation reduces the therapeutic response to mTOR kinase inhibitors
10.1016/j.celrep.2023.112764 · 2023 · External reference
p53 Deletion or hotspot mutations enhance mTORC1 activity by altering lysosomal dynamics of TSC2 and Rheb
10.1158/1541-7786.mcr-15-0159 · 2016 · External reference
Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer
10.1158/0008-5472.can-14-3362 · 2016 · External reference
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
10.1073/pnas.1310230110 · 2013 · External reference
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
10.1084/jem.20131916 · 2014 · External reference
Metformin enhances the antitumor activity of CD8+ T lymphocytes via the AMPK-miR-107-eomes-PD-1 pathway
10.4049/jimmunol.1901213 · 2020 · External reference
Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion
10.1016/j.immuni.2016.07.008 · 2016 · External reference
Activation of mTORC1 at late endosomes misdirects T cell fate decision in older individuals
10.1126/sciimmunol.abg0791 · 2021 · External reference
TIGIT as an emerging immune checkpoint
10.1111/cei.13407 · 2020 · External reference
mTOR inhibitor use in head and neck squamous cell carcinoma: a meta-analysis on survival, tumor response, and toxicity
10.1002/lio2.370 · 2020 · External reference
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
2018 · External reference
